Reduction in Herpes Zoster Antiviral Use Since the Introduction of the Live-Attenuated Zoster Vaccine on Australia’s National Immunisation Program: A Population-Based Study from 1994 to 2019

INTRODUCTION: Zostavax, the live-attenuated vaccine used to prevent herpes zoster (HZ), has been available to individuals aged 70 and 71–79 years (phased catch-up) via Australia’s National Immunisation Program (NIP) since 2016. There are limited data characterising the incidence of HZ at the level o...

Descripción completa

Detalles Bibliográficos
Autores principales: Phakey, Sachin, Rogers, Sophie L., Hall, Anthony J., Lim, Lyndell L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925617/
https://www.ncbi.nlm.nih.gov/pubmed/36626109
http://dx.doi.org/10.1007/s40121-022-00749-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925617/
https://www.ncbi.nlm.nih.gov/pubmed/36626109
http://dx.doi.org/10.1007/s40121-022-00749-y

Ejemplares similares